Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. develops AI-driven precision antibody therapies for cardiometabolic, obesity and cardiopulmonary diseases. Company news commonly covers pipeline updates for IBIO-600, a long-acting anti-myostatin monoclonal antibody, and IBIO-610, an Activin E antibody candidate, along with preclinical body-composition data and regulatory clearances tied to early clinical development.
Recurring updates also include iBio's antibody-discovery approach, including computational biology and epitope-steering, as well as financial results, capital financing, investor-conference presentations and board or committee changes.
iBio, Inc. (NYSE AMERICAN:IBIO) will be added to the Russell 2000 and Russell 3000 indexes effective June 29, 2020. This addition signals significant progress in the company’s journey to enhance shareholder value. CEO Tom Isett highlighted recent achievements, including the launch of the FastGlycaneering Development Service™ and collaborations for a bio-better rituximab. Furthermore, iBio is advancing COVID-19 vaccine candidates, with preclinical data expected in Q3-2020, showcasing potential future milestones for the company.
iBio has been selected by IBM Watson Health to receive 18 months of complimentary use of the IBM Clinical Development (ICD) solution, aimed at facilitating the company's COVID-19 vaccine trials. This recognition highlights iBio's potential in vaccine development, among hundreds of applicants. Data from preclinical studies of the COVID-19 vaccine candidates IBIO-200 and IBIO-201 is expected in Q3-2020. The partnership is anticipated to accelerate clinical trial processes and enhance data management efficiency.
iBio announced the initiation of preclinical immunization studies for its second COVID-19 vaccine, IBIO-201, featuring a subunit vaccine combining SARS-CoV-2 spike protein antigens and the proprietary LicKM booster technology. This development could enhance immune response and manufacturing capacity. iBio's plant-based FastPharming System™ facilitates scalable production, potentially yielding hundreds of millions of doses. The vaccine's efficacy is backed by prior research, indicating the promise of LicKM technology in achieving prolonged immunity.